Alnylam Expands RNAi Pipeline with 10th Roundtable Series
Event summary
- Alnylam to host its 10th RNAi Roundtable webcast series, featuring updates on three pipeline programs: ALN-6400, Zilebesiran, and ALN-HTT02.
- Webinars scheduled for June 25, September 17, and October 26, 2026, with replays available post-event.
- Company aims to expand pipeline to over 40 clinical programs by 2030, up from 25 today.
- Alnylam 2030 strategy includes leveraging AI to accelerate discovery and expanding into new tissues.
The big picture
Alnylam's 10th RNAi Roundtable series underscores its leadership in RNAi therapeutics and commitment to sustainable innovation. The company's ambitious 2030 goals reflect broader industry trends toward AI-driven drug discovery and expanded pipeline portfolios. With partnerships spanning Roche, Novartis, Sanofi, and Regeneron, Alnylam is positioning itself as a key player in transforming human health through RNAi.
What we're watching
- Pipeline Execution
- Whether Alnylam can deliver on its goal of 40+ clinical programs by 2030, given current pipeline of 25.
- AI Integration
- The pace at which AI technologies will accelerate Alnylam's discovery platform and optimize R&D.
- Market Expansion
- How successful Alnylam will be in expanding into new tissues and addressing unmet clinical needs.